tbuckley/cabot-search huggingface dataset:
Junior doctor is found dead at Taunton hospital
Authors: Abi Rimmer
Journal: BMJ (2017)

A junior doctor has died from an apparent suicide at an NHS hospital in Taunton, Somerset.

Musgrove Park Hospital has confirmed that the male junior doctor, who has not been named, died on site late on the night of Monday 31 July, apparently by taking his own life.

Sam Barrell, chief executive of the hospital, said, “We are terribly upset by the death of our colleague and we are doing …
Survival After Laparoscopic vs Abdominal Hysterectomy—Reply
Authors: Val Gebski, Monika Janda, Andreas Obermair
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of autologous platelet-rich plasma combined with hyaluronic acid on skin facial rejuvenation: A prospective study
Authors: Barbara Hersant, Mounia SidAhmed-Mezi, Jeremy Niddam, Simone La Padula, Warren Noel, Khaled Ezzedine, Anne Marie Rodriguez, Jean Paul Meningaud
Journal: Journal of the American Academy of Dermatology (2017)

Corresponding medical records of included cases were then reviewed, with cases of icSCC treated via curettage alone included in this study.Patient and tumor characteristics were recorded, including duration of follow-up through the end of the study period (May 17, 2015).Tumors were considered recurrent if there was documentation of clinician or patient suspicion for recurrence with histologic confirmation of icSCC at the same site.Overall, 89 individual lesions from 80 unique patients met inclusion criteria and were included in this study.Duration of follow-up extended from 0 to 2502 days (6.8 years), with a median of 6 years.Most patients were male, with a mean age of 76 years at the time of diagnosis (Table I).Forty-four percent of lesions were located in low-risk sites, with a mean pretreatment size of 0.9 cm (range, 0.3-2.5 cm).Most lesions (76%) had tumor present at histologic margins, and 91% were well-differentiated (Table II).Three recurrences were identified (overall cure rate, 97%), 2 of which were located on high-risk sites, and 2 of the 3 recurrent lesions initially had positive histologic margins (Table II).One recurrent lesion was located on a high-risk site and was present at histologic margins before treatment with curettage.All recurrent lesions were welldifferentiated histologically (Table II).Time to recurrence (days) was 60, 68, and 78; 2 recurrences were initially curetted by the same staff dermatologist.Limitations of this study include incomplete medical records and suboptimal site documentation, potentially leading to missed recurrent tumors.Additionally, variation in curettage technique may have been present between clinicians (eg, disposable versus reusable curettes, number of passes with the curette) and practitioners may have preselected tumors and patients with certain characteristics for curettage alone.In conclusion, this study demonstrated a 97% cure rate of icSCC by curettage alone. 4 Providers with adequate training in this technique should consider this treatment in icSCC with comparable features because it can be an efficient and effective modality for treating this tumor.Our small sample size precludes strong recommendations for precise tumor or technique selection.A prospective study is needed to further explore risk factors for recurrence as well as cosmetic outcomes, healing time, and complications associated with this procedure.
Notch Shapes the Innate Immunophenotype in Breast Cancer
Authors: Qiang Shen, Brenda Cohen, Weiyue Zheng, Ramtin Rahbar, Bernard Martin, Kiichi Murakami, Sara Lamorte, Patrycja Thompson, Hal Berman, Juan Carlos Zúñiga-Pflücker, Pamela S. Ohashi, Michael Reedijk
Journal: Cancer Discovery (2017)

Notch activation, which is associated with basal-like breast cancer (BLBC), normally directs tissue patterning, suggesting that it may shape the tumor microenvironment. Here, we show that Notch in tumor cells regulates the expression of two powerful proinflammatory cytokines, IL1β and CCL2, and the recruitment of tumor-associated macrophages (TAM). Notch also regulates TGFβ-mediated activation of tumor cells by TAMs, closing a Notch-dependent paracrine signaling loop between these two cell types. We use a mouse model in which Notch can be regulated in spontaneous mammary carcinoma to confirm that IL1β and CCL2 production, and macrophage recruitment are Notch-dependent. In human disease, expression array analyses demonstrate a striking association between Notch activation, IL1β and CCL2 production, macrophage infiltration, and BLBC. These findings place Notch at the nexus of a vicious cycle of macrophage infiltration and amplified cytokine secretion and provide immunotherapeutic opportunities in BLBC.Significance: BLBC is aggressive and has an unmet need for effective targeted treatment. Our data highlight immunotherapeutic opportunities in Notch-activated BLBC. Effective IL1β and CCL2 antagonists are currently in clinical review to treat benign inflammatory disease, and their transition to the cancer clinic could have a rapid impact. Cancer Discov; 7(11); 1320-35. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1201.
THE PROTECTIVE EFFECTS OF VARIOUS WARM-UP MODALITIES ON EXERCISE-INDUCED BRONCHOSPASM (EIB) IN NON-ASTHMATIC ATHLETES
Authors: Jae Seung Chang, Young Hee Lee, In Deok Kong
Journal: British Journal of Sports Medicine (2017)

Background Exercise-induced bronchospasm (EIB) that is a transient airway obstruction occurring after strenuous exertion can occur in non-asthmatic athletes as well. However acute effects of different warm-up modalities on EIB in athletes without asthma remain uncertain. Objective The aim of this study was to determine the efficacy of different warm-up modalities on improving EIB in non-asthmatic athletes. Design Randomized crossover controlled trial. Each participant performed four experimental trials on nonconsecutive days, consisting of exercise challenge test for 6 min (at velocity of 90%HR max ) following either continuous warm-up (CW), high-intensity interval warm-up (HW), modified warm-up (MW) or no warm-up (NW). Pulmonary functions were measured prior to each experimental trial, and repeated before and at 1, 5, 10, 15, 20 min after exercise challenge. Setting Research laboratory in a university setting. Participants Eleven competitive collegiate athletes. Interventions CW consisted of 15-min run at a velocity corresponding to 60%VO 2max , HW involved 8 repetitions of 30-sec run (45-sec rest between bouts of running) at an intensity equivalent to 90–100%VO 2max , and MW was composed with combination of HW (6 repetitions) and CW (5-min). Main Outcome Measurements The main spirometric parameters of airway obstruction included forced expiratory volume in 1 second (FEV 1.0 ), forced vital capacity (FVC), and their ratio (FEV 1.0 /FVC), forced mid-expiratory flow (FEF 25–75 ) and peak expiratory flow (PEF). Results The mean maximum percent fall in pre- to post-exercise FEV 1.0 for all subjects during the EIB screening test was −17.7±6.5%. The mean maximum percent decrease in post-exercise FEV 1.0 significantly decreased to −4.0±5.5% and −5.2±3.5% following CW and MW, respectively (all p &lt;0.01). All of three warm-up modalities significantly attenuated the mean percentage fall in FEV 1.0 at 5, 10 and 15 min compared to control (all p &lt;0.05). Conclusions These data indicate that all of three warm-up modalities have a protective effect against developing EIB in non-asthmatic athletes.
Abstract #1926: A small-molecule inhibitor, targeting FAK and Mdm-2 interaction, blocks breast and colon tumorigenesis in vivo.
Authors: Nadia Palma, Vita Golubovskaya, Min Zheng, Andrew Magis, David Ostrov, William Cance
Journal: Cancer Research (2009)

Focal Adhesion Kinase (FAK) is a non-receptor kinase that is overexpressed in many types of tumors and plays an important role in motility, adhesion, proliferation, invasion, angiogenesis and survival.  Recently, FAK has been proposed to be a potential target of cancer therapy. We developed a novel cancer therapy approach, targeting FAK protein-protein interactions by computer modeling and screening of NCI small molecule drugs database. Since recently, FAK N-terminal domain (FAK-NT) has been shown to bind Mdm-2 protein, we targeted FAK-NT and Mdm-2 interaction. Screening of >140,000 small molecule compounds with drug-like characteristics and highest scores, targeting FAK-Mdm-2, identified 24 compounds (called M drugs) that have been ordered from NCI. MTT assays with 36 compounds were performed on several different cancer cell lines, including breast, melanoma, colon and pancreatic cancer cells. We identified M13 compound that significantly decreased viability  in vitro  in most of the cancer cells. The effect of M13 was dose-dependent. M13 compound increased level of apoptotic Mdm-2 and decreased pro-survival FAK protein level in BT474 breast cancer cells. In addition, M13 decreased breast cancer tumorigenesis  in vivo . The effect of M13 was p53-independent, as it decreased viability  in vitro  and tumorigenesis  in vivo  in both HCT116p53 - / -  and HCTp53+/ +  colon cancer cells. The data suggest a novel approach targeting FAK and Mdm-2 protein interaction that can provide future effective therapeutics.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1926.
Incorporating Genetic Testing Into Cardiovascular Practice
Authors: Elizabeth M. McNally
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 347: Zebrafish Insertional Cardiac (ZIC) Mutants: a Living Genomic Resource for Cardiac Biology
Authors: Weibin Liu, Yonghe Ding, Beninio Gore, Stephen C Ekker, Xiaolei Xu
Journal: Circulation Research (2013)

The human genome encodes about 20,000 genes and only a fraction of them are expressed in the heart. We hypothesized that annotation of this category of genes may facilitate our understanding of cardiac development and function. Recently, we reported a pilot insertional mutagenesis screening in zebrafish to annotate cardiac gene functions using a gene-break transposon (GBT). It demonstrated the feasibility of generation of a Zebrafish Insertional Cardiac (ZIC) mutant collection by screening gene expression in the embryonic heart. Here, we report an alternative strategy to identify cardiac mutants based on adult heart expression, and explore the application of expanded ZIC lines for understanding cardiac biology. From 203 GBT lines, we identified 34 lines with detectable expression in the dissected adult hearts. Various expression levels of the tagged genes were detected in embryonic hearts. Based on their tissue-specific expression, the candidate ZIC lines can be grouped into myocardium lines, endocardium lines, or both. Based on their subcellular expression, myocardium ZIC lines can be further categorized into sarcomeric lines, mitochondrial lines, and/or nucleic lines. Phenotypic analysis is being conducted to identify recessive mutants including embryonic lethal lines. We will present the current status of our ZIC collection, and discuss its application as a genomic resource platform for elucidating cardiac biology. Our data suggest that ~15% genes in the whole genome might have detectable cardiac expression. The sensitivity of screening for cardiac genes at adult stage is higher than that at embryonic stage (34/203 versus 18/322). We plan to expand the ZIC collection by screening 1,000 GBT lines that are being generated at Mayo Clinic. It is expected that this living mutant collection of cardiac genes will open doors to systematic annotation of novel cardiac genes and forward cardiac mutagenesis screening.
OP0347-HPR Training rheumatology nurse specialists: what does the future hold?
Authors: MK Nisar, J Begum
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Since the introduction of the Rheumatology nursing in the UK in 1980s, there has been gradual development of the "specialty". Despite the proven benefits, both clinical and economical, of a well-trained rheumatology nurse specialist and the evolution of the role, there is a lack of a clear career path for the profession. <h3>Objectives</h3> We undertook a pilot survey to understand the present climate of rheumatology practitioner training in the region. <h3>Methods</h3> Following a focus group discussion of an "ideal" development route for rheumatology practitioners, ten items were unanimously identified as areas for job progression. These included appropriate induction, prescribing skills, involvement in research and education, opportunities for combined working and scope for clinical development. A questionnaire was created based on these items and mailed to all the rheumatology units in the East of England. Replies were compiled to ascertain the current picture of regional training. <h3>Results</h3> There are 19 centres providing rheumatology services in the region with 51 rheumatology practitioners. All of them (100%) replied to the questionnaire. Only four units (21%) provide formal induction programme for training. 11/19 (57%) have nurse prescribers. All providers replied positive to the question pertaining nurses9 participation in research and audit; 12 (63%) have presented locally or nationally and eight (42%) have submitted posters to conferences. 12 centres have partly nurse delivered early arthritis pathway and 13 have access to departmental ultrasound. Ten units provide patient educational events. <h3>Conclusions</h3> This is a pioneering survey outlining access of rheumatology practitioners and nurse specialists to developmental opportunities. This initiative highlights a wide variation in the provision of clear career pathway regionally. Though most centres are delivering contemporary services, these are not being used effectively for developing key team members. There is lack of formal induction programme. Though most nurses are involved in audit, less than a quarter are presenting at any level and even fewer are publishing research endeavours. Prescribing is limited to 15/51 (29%) members. Less than 20% are training to do intra-articular injections or learning musculoskeletal ultrasound. Despite patient education being a core skill for this group, only 10 units deliver these as a formal event. In conculsion, there is wide variation in the provision of career advancing opportunities to rheumatology nurse specialists. This can potentially have a negative impact on staff recruitment and retention. There is a need for improving standards and delivery of rheumatology professionals9 career development. <h3>Disclosure of Interest</h3> None declared
Increasing Incidence but Decreasing Awareness of Type 1 Diabetes in Sweden
Authors: Johnny Ludvigsson
Journal: Diabetes Care (2017)

In Finland, which has the highest incidence in the world of type 1 diabetes (T1D) among children, the incidence seems to level off. Sweden, which has the second highest incidence, is said to have an incidence leveling off at ∼40–44 per 100,000 children per year (1). The environmental factors explaining the T1D increase (2) should have reached their maximum. Childhood obesity is no longer increasing in Sweden and a plateau of T1D incidence would fit the β-cell stress hypothesis; however, there could be other explanations.

To elucidate the situation data from the official annual reports from SWEDIABKIDS, the national register of children with newly diagnosed diabetes in Sweden (3), data have been analyzed regarding HbA1c and ketoacidosis at onset, and to get the incidence of T1D in children <15 years of age. These data have been added to published data (1, …
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council
Authors: Eric L. Simpson, Marjolein Bruin-Weller, Carsten Flohr, Michael R. Ardern-Jones, Sebastien Barbarot, Mette Deleuran, Thomas Bieber, Christian Vestergaard, Sara J. Brown, Michael J. Cork, Aaron M. Drucker, Lawrence F. Eichenfield, Regina Foelster-Holst, Emma Guttman-Yassky, Audrey Nosbaum, Nick J. Reynolds, Jonathan I. Silverberg, Jochen Schmitt, Marieke M.B. Seyger, Phyllis I. Spuls, Jean-Francois Stalder, John C. Su, Roberto Takaoka, Claudia Traidl-Hoffmann, Jacob P. Thyssen, Jorien van der Schaft, Andreas Wollenberg, Alan D. Irvine, Amy S. Paller
Journal: Journal of the American Academy of Dermatology (2017)

BackgroundAlthough most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking.ObjectiveTo guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient.MethodsA subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion.ResultsWe recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy.LimitationsOur work is a consensus statement, not a systematic review.ConclusionThe decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies.
05.14 Rna-seq profiling of hematopoietic stem cells in murine systemic lupus erythematosus (sle): validation and functional characterisation
Authors: Maria Grigoriou, Marina Anastasiou, Panayotis Verginis, Pavlos Pavlidis, Christoforos Nikolaou, George Bertsias, Dimitrios T Boumpas, Aggelos Banos
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Hematopoietic Stem Cells (HSCs) give rise to all blood cell lineages, which have been implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE). We reasoned that the fundamental immune aberrations in SLE –genetic or epigenetic- may be traced back to the HSC population. We are validating and functionally characterising the molecular targets of RNA-seq transcriptome profiling in the HSC compartment of lupus mice. <h3>Materials and methods</h3> HSCs were isolated from either control C57/BL6 or NZBxNZW/F1 lupus prone mice bone marrow (n=15±5). The selection markers used are Lin<sup>-</sup>Sca-1<sup>+</sup>c-Kit<sup>+</sup> for LSK compartment and intermediate progenitors as common lymphoid and myeloid progenitors were characterised. Flow cytometry cell sorting was utilised for enumeration, RNA extraction, cell cycle analysis and CFU assays. Lentiviral vectors of either overexpressing or silencing gene targets were constructed. <h3>Results</h3> We identified increased frequencies (~3% pre-diseased vs ~5% diseased, p&lt;0.05) as well as absolute numbers (80–100×10<sup>3</sup> pre-diseased vs 100–150×10<sup>3</sup> diseased, p&lt;0.05) of HSCs in the BM of lupus NZBxNZW/F1 mice with established disease as compared to pre-diseased NZBxNZW/F1 or control C57/BL6 mice. Bone marrow populations such as hematopoietic stem progenitors cells (HSPCs), lymphoid and myeloid lineages differed in homogeneity depending upon either age or disease, suggesting alterations in HSC potential under inflammatory conditions. The frequency of common myeloid progenitors in pre-diseased mice is higher compared to control mice. Accordingly, serum from F1 pre-diseased mice promoted healthy HSCs to proliferation and skewed their differentiation towards to myeloid lineage. Transcriptome analysis by RNA-seq of HSCs from lupus mice revealed 294 differentially expressed genes (DEGs) (FC &gt;1.5, q&lt;0.05) in diseased lupus mice compared to pre-diseased. DEGs show enrichment in transcription factors (such as Fbxw7, Cebpα, Blimp1, Hif1α) involved in hematopoiesis regulation of immune responses during inflammation and autoimmune diseases and HSC function and homeostasis. We have constructed lentiviral vectors to silence Cebpα gene expression for further functional analysis of its impact in HSCs under inflammatory conditions. <h3>Conclusions</h3> Transcription factors involved in hematopoiesis such as Cebpα are enriched in lupus HSCs and may drive the increased proliferation and myeloid differentiation observed within the inflammatory milieu of the disease.
The 10-Year Prognostic Value of Zero and Minimal CAC
Authors: Parag H. Joshi, Michael J. Blaha, Matthew J. Budoff, Michael D. Miedema, Robyn L. McClelland, Joao A.C. Lima, Arthur S. Agatston, Ron Blankstein, Roger S. Blumenthal, Khurram Nasir
Journal: JACC. Cardiovascular imaging (2017)